The popularity of Viagra initially drove a boom for pharma, however recent developments present a murky scenario for shareholders. Off-patent versions are reducing profits, and continued litigation add more difficulty https://mathetxkl918279.educationalimpactblog.com/62725569/the-blue-pill-and-big-pharma-a-volatile-play